Merck & Co., Inc. (MRK)
NYSE: MRK · Real-Time Price · USD
99.72
-1.17 (-1.16%)
At close: Dec 5, 2025, 4:00 PM EST
99.80
+0.08 (0.08%)
After-hours: Dec 5, 2025, 7:59 PM EST
Merck & Co. Revenue
Merck & Co. had revenue of $17.28B in the quarter ending September 30, 2025, with 3.72% growth. This brings the company's revenue in the last twelve months to $64.24B, up 1.68% year-over-year. In the year 2024, Merck & Co. had annual revenue of $64.17B with 6.74% growth.
Revenue (ttm)
$64.24B
Revenue Growth
+1.68%
P/S Ratio
3.90
Revenue / Employee
$856,467
Employees
75,000
Market Cap
247.51B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 64.17B | 4.05B | 6.74% |
| Dec 31, 2023 | 60.12B | 832.00M | 1.40% |
| Dec 31, 2022 | 59.28B | 10.58B | 21.72% |
| Dec 31, 2021 | 48.70B | 7.19B | 17.31% |
| Dec 31, 2020 | 41.52B | 2.40B | 6.13% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
| Abbott Laboratories | 43.84B |
MRK News
- 8 hours ago - Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones? - The Motley Fool
- 9 hours ago - Merck's Stock is Suddenly Soaring, but Is the Struggling Healthcare Giant a Buy? - The Motley Fool
- 1 day ago - 5 Relatively Secure And Cheap Dividend Stocks, Yields Up To 8% (December 2025) - Seeking Alpha
- 2 days ago - Do These 3 Healthcare Stocks Need a Checkup? - The Motley Fool
- 2 days ago - Vaccine makers raise concerns over US panel's shift away from hepatitis B shots for newborns - Reuters
- 2 days ago - Is This Pharmaceutical Giant a Buy After a Major Acquisition? - The Motley Fool
- 2 days ago - These Are the 3 Hottest Stocks in the S&P 500 Heading Into the New Year. Should You Invest in Them? - The Motley Fool
- 3 days ago - Pliant Cancer Drug Boosts Responses When Paired With Merck's Blockbuster Keytruda In Tough-To-Treat Tumors - Benzinga